Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052839 | 1.00 | HTT (0.33) | HTTKDM4ENPC1KMT2AMEN1 | |
| SCHEMBL3066884 | 0.91 | RAB9A (0.36) | HTTKDM4ENPC1KMT2AMEN1 | |
| SCHEMBL3066888 | 0.91 | RAB9A (0.36) | HTTKDM4ENPC1KMT2AMEN1 | |
| SCHEMBL3070288 | 0.82 | NPC1 (0.33) | HTTKDM4ENPC1KMT2AMEN1 | |
| SCHEMBL3070291 | 0.82 | NPC1 (0.33) | HTTKDM4ENPC1KMT2AMEN1 | |
| SCHEMBL3060327 | 0.78 | KDM4E (0.39) | HTTKDM4ENPC1KMT2AGAA | |
| SCHEMBL4506693 | 0.78 | KDM4E (0.39) | HTTKDM4ENPC1KMT2AGAA | |
| SCHEMBL5015622 | 0.78 | KDM4E (0.39) | HTTKDM4ENPC1KMT2AGAA | |
| SCHEMBL3065224 | 0.78 | KDM4E (0.36) | HTTKDM4EKMT2AMEN1MAPT | |
| SCHEMBL3065228 | 0.78 | KDM4E (0.36) | HTTKDM4EKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | HTT 2271/4885KDM4E 4486/4885NPC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.